MedTrace Logo

Therapeutic Exploratory Study of CWP-0403

NCT00888719 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2010-11-05

No results posted yet for this study

Summary

Objective of the trial is to assess dose-dependency, efficacy and safety and to estimate optimum dosage for confirmatory study of CWP-0403 50mg, 100mg given twice daily for 12 weeks to type 2 diabetes patients who are insufficiently controlled by diet and exercise in comparison to placebo.

Conditions

Interventions

DRUG

CWP-0403 100mg

100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks

DRUG

placebo

Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets. Twice a day, 1 tablet at a time for 12 weeks

DRUG

CWP-0403 50mg

50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • KunHo Yoon · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888719 on ClinicalTrials.gov